Translocation Clinical Trials Translocation RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Phase 1 Study VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Conditions:   Relapsed Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Richter Syndrome;   MYC Amplification;   MYC Overexpression;   MYC Translocation Intervention:   Drug: VIP152 Sponsor:   Vincerx Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2021 Category: Research Source Type: clinical trials

A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Conditions:   Relapsed Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Richter Syndrome;   MYC Amplification;   MYC Overexpression;   MYC Translocation Intervention:   Drug: VIP152 Sponsor:   Vincerx Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2021 Category: Research Source Type: clinical trials

Treatment of Relapsed/Refractory Multiple Myeloma With t 11;14 Translocation Using BGB-11417 With Dexamethasone; Also Using BGB-11417 in Combination With Dexamethasone and Carfilzomib.
Condition:   Relapsed/Refractory Multiple Myeloma Interventions:   Drug: BGB-11417 + Dexamethasone;   Drug: BGB-11417 + Dexamethasone + Carfilzomib Sponsor:   BeiGene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 22, 2021 Category: Research Source Type: clinical trials